2026-W46 · Nov 9–Nov 15 · Company · Profile · published
Becton Dickinson company profile · medical devices, instruments & reagents · history · financial snapshot · S&P 500 rank #218 · 碧迪公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | BDX (NYSE) |
| Company | Becton, Dickinson and Company |
| GICS sector / industry | Health Care (XLV) / Health Care Equipment & Supplies |
| S&P 500 rank (by weight) | #218 · 0.08% (Oct 30, 2026) |
| Sector rank (by market cap) | #27 in Health Care (Oct 30, 2026) |
| Share price (frozen benchmark) | $197.88 (Oct 30, 2026) |
| Headquarters | Franklin Lakes, New Jersey |
| Founded | 1897 (by Maxwell Becton and Fairleigh S. Dickinson) |
| CEO | Tom Polen (Chairman, CEO and President) |
| Employees | about 72,000 (2025) |
| Market cap | $53.90B (Oct 30, 2026) |
WHAT IT DOES
Becton, Dickinson — known as BD — is a global medical technology company that manufactures and sells medical devices, instrument systems and reagents used in drug delivery, diagnostics and research. Hospitals, laboratories and clinics use its syringes, catheters, diagnostic instruments and specimen-collection products every day.
The model is consumables plus instruments: single-use devices generate recurring revenue, while diagnostic and laboratory instruments place the consumables that follow. FY2025 revenues were $21,840M, up 8.2% from $20,178M, operating income was $2,578M and net income was $1,678M.
BD reports three segments — BD Medical, BD Interventional and BD Life Sciences — and its FY2025 figures here are as originally reported. A later portfolio separation (Biosciences and Diagnostic Solutions) recast later periods; the recast figures are not used in this profile.
BUSINESS SEGMENTS — FY2025 NET SALES
| Segment | Revenue | Share | YoY |
|---|---|---|---|
| BD Medical | — | — | — |
| BD Interventional | — | — | — |
| BD Life Sciences | — | — | — |
HISTORY
| Year | Milestone |
|---|---|
| 1897 | Founded in New York City by Maxwell Becton and Fairleigh S. Dickinson |
| 1906 | Incorporated as Becton, Dickinson & Company |
| 1962 | Initial public offering |
| 2015 | Acquires CareFusion, expanding medication management |
| 2017 | Acquires C. R. Bard, expanding interventional devices |
| 2025 | FY2025 revenues reach $21,840M for the year ended Sep 30, 2025 |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT — FY2025
| Total revenues | $21,840M (+8.2% YoY) |
| Gross profit | $9,925M |
| Operating income | $2,578M |
| Net income | $1,678M |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
BD is the S&P 500's medical-consumables name: at a 0.08% index weight and #27 in Health Care by market cap, it is the index's main exposure to hospital consumables and diagnostic instruments.
Its volumes are a standing read on hospital activity — syringe, catheter and diagnostic demand moves with procedures before it shows up in hospital revenue.
SOURCES & METHODOLOGY
| Market data | Slickcharts S&P 500 by weight (rank, weight, price — Oct 30, 2026 close) |
| Financials | Becton, Dickinson FY2025 Form 10-K results (fiscal year ended Sep 30, 2025), company profile sources |
| Sector classification | GICS (Health Care Equipment & Supplies) via the List of S&P 500 companies (Wikipedia) |
| Library data | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information. |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 代碼 | BDX(NYSE) |
| 公司 | Becton, Dickinson and Company |
| GICS 板塊/行業 | 醫療保健(XLV)/醫療保健設備與用品 |
| 標普500排名(按權重) | #218 · 0.08%(2026 年 10 月 30 日) |
| 板塊內排名(按市值) | 醫療保健第 #27(2026 年 10 月 30 日) |
| 股價(凍結基準) | $197.88(2026 年 10 月 30 日) |
| 總部 | 美國新澤西州富蘭克林湖 |
| 成立 | 1897 年(Maxwell Becton 與 Fairleigh S. Dickinson 創辦) |
| 行政總裁 | Tom Polen(董事長、行政總裁兼總裁) |
| 員工 | 約 72,000(2025 年) |
| 市值 | $53.90B(2026 年 10 月 30 日) |
業務概覽
Becton, Dickinson(簡稱 BD)是一家全球醫療科技公司,製造及銷售藥物輸送、診斷與研究用的醫療裝置、儀器系統與試劑。醫院、實驗室與診所每日使用其注射器、導管、診斷儀器與樣本採集產品。
其模式為耗材加儀器:一次性裝置帶來經常性收入,診斷與實驗室儀器則帶動後續耗材。FY2025 收入為 $21,840M,同比增長 8.2%(FY2024 為 $20,178M),營業利潤為 $2,578M,淨利潤為 $1,678M。
BD 申報三個板塊——BD Medical、BD Interventional 與 BD Life Sciences;此處 FY2025 數字按原申報列示。其後一次組合分拆(Biosciences 與 Diagnostic Solutions)重列了其後期間;重列數字本簡介不予採用。
業務板塊 — FY2025
| 板塊 | 收入 | 佔比 | 同比 |
|---|---|---|---|
| BD Medical | — | — | — |
| BD Interventional | — | — | — |
| BD Life Sciences | — | — | — |
歷史沿革
| 年份 | 里程碑 |
|---|---|
| 1897 | 在紐約市創立,由 Maxwell Becton 與 Fairleigh S. Dickinson 創辦 |
| 1906 | 註冊為 Becton, Dickinson & Company |
| 1962 | 首次公開招股 |
| 2015 | 收購 CareFusion,擴大藥物管理業務 |
| 2017 | 收購 C. R. Bard,擴大介入裝置業務 |
| 2025 | FY2025 收入達 $21,840M,財政年度截至 2025 年 9 月 30 日 |
競爭地位
財務快照 — FY2025
| 總收入 | $21,840M(同比 +8.2%) |
| 毛利 | $9,925M |
| 營業利潤 | $2,578M |
| 淨利潤 | $1,678M |
主要風險
對標普500的重要性
碧迪是標普500的醫療耗材標的:指數權重 0.08%、醫療保健板塊市值第 #27,是指數對醫院耗材與診斷儀器的主要敞口。
其銷量是醫院活動的常設讀數——注射器、導管與診斷需求隨手術量變動,往往先於醫院收入反映。
來源與方法
| 市場數據 | Slickcharts 標普500權重榜(排名、權重、價格——2026 年 10 月 30 日收盤) |
| 財務 | 碧迪 FY2025 Form 10-K 業績(財政年度截至 2025 年 9 月 30 日)、公司簡介來源 |
| 板塊分類 | GICS(醫療保健設備與用品),據 S&P 500 公司清單(Wikipedia) |
| 圖庫數據 | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。 SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。 |
來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份) · SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-10-31 11:40 · updated 2026-11-14 23:01 · rev 7